Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.34 |
| ▸ | CDK4 | P11802 | 4/20 | 0.34 |
| ▸ | CCND1 | P24385 | 4/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148645 | 0.85 | CHEK1 (0.35) | CHEK1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL12046456 | 0.80 | CHEK1 (0.33) | CHEK1KMT2AKDM4EL3MBTL1LMNA | |
| SCHEMBL1148734 | 0.75 | KMT2A (0.45) | CHEK1KMT2AKDM4ELMNAALDH1A1 | |
| SCHEMBL12046461 | 0.73 | FGFR1 (0.35) | CHEK1KDM4ELMNAALDH1A1POLB | |
| SCHEMBL1147883 | 0.71 | HSP90AA1 (0.37) | CHEK1KDM4ELMNAALDH1A1POLB | |
| SCHEMBL1148531 | 0.70 | CHEK1 (0.34) | CHEK1KDM4ELMNAALDH1A1POLB | |
| SCHEMBL1148680 | 0.69 | HSP90AA1 (0.34) | KMT2AKDM4ELMNAALDH1A1POLB | |
| SCHEMBL1148628 | 0.68 | MEN1 (0.35) | KMT2AKDM4ELMNAALDH1A1POLB | |
| SCHEMBL1148627 | 0.68 | KMT2A (0.45) | CHEK1KMT2AKDM4ELMNAALDH1A1 | |
| SCHEMBL1147836 | 0.67 | MEN1 (0.42) | CHEK1CDK4CCND1CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-8993608-B2 | Method for inhibiting topoisomerase II | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8969396-B2 | Method for treating a B-raf associated cancer with an Hsp90 inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140221375-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140141511-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130338155-A1 | METHOD FOR TREATING INFECTIONS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20110319404-A1 | METHOD FOR TREATING NON-HODKIN'S LYMPHOMA | SYNTA PHARMACEUTICALS CORP. | 2011-12-29 | — | — | US | disclosed |
| US-8063083-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8034834-B2 | Method for treating proliferative disorders with HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100280032-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221375-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | CHEK1 178/4885CDK4 93/4885CCND1 1827/4885 |
| US-20130338155-A1 | METHOD FOR TREATING INFECTIONS | HSP90AB1, HSP90B1, HSP90AA1 | CHEK1 3328/4885CDK4 2526/4885CCND1 4814/4885 |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | CHEK1 245/4885CDK4 1038/4885CCND1 2883/4885 |
| US-20100280032-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | CHEK1 4867/4885CDK4 4174/4885CCND1 4872/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | CHEK1 809/4885CDK4 122/4885CCND1 1394/4885 |
| US-20140141511-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | CHEK1 4867/4885CDK4 4174/4885CCND1 4872/4885 |
| US-20110319404-A1 | METHOD FOR TREATING NON-HODKIN'S LYMPHOMA | HSP90AB1, HSP90AA1, HSP90B1 | CHEK1 2485/4885CDK4 2502/4885CCND1 4415/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | CHEK1 2301/4885CDK4 2040/4885CCND1 4420/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | CHEK1 245/4885CDK4 1038/4885CCND1 2883/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | CHEK1 4867/4885CDK4 4174/4885CCND1 4872/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | CHEK1 4867/4885CDK4 4174/4885CCND1 4872/4885 |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | HSP90AB1, HSP90B1, HSP90AA1 | CHEK1 3351/4885CDK4 2583/4885CCND1 4789/4885 |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | CHEK1 178/4885CDK4 93/4885CCND1 1827/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | CHEK1 809/4885CDK4 122/4885CCND1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.